SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-Q/A
                               (Amendment No. 1)
               (Amending Item 6 to file a corrected Exhibit 27.1)

(Mark One)

[X]  Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934 for the quarterly period ended September 30, 1998 or

[ ]  Transition  report  pursuant  to Section  13 or 15(d) of the  Securities
     Exchange Act of 1934 for the transition period from _____ to _____.

                       Commission File Number: 333-22359

                              BIONX IMPLANTS, INC.
             (Exact name of registrant as specified in its charter)

          Delaware                                         22-3458598
(State or other jurisdiction of                    (I.R.S. Employer
 incorporation or organization)                    Identification No.)


                            1777 Sentry Parkway West
                            Gwynedd Hall, Suite 400
                         Blue Bell, Pennsylvania 19422
          (Address of principal executive office, including zip code)

                                  215-643-5000
              (Registrant's telephone number, including area code)
________________________________________________________________________________
     (Former name, former address and former fiscal year, if changed since
                                  last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports)  and  (2)  has  been  subject  to such  filing
requirements for the past 90 days.

               Yes  X                               No___

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

At November 3, 1998,  there were  8,922,076  shares of Common  Stock,  par value
$.0019 per share, outstanding.

<PAGE>

Item 6. Exhibits and Reports on Form 8-K*

     (a) The following  exhibits are filed as part of this  Quarterly  Report on
Form 10-Q:

     No. 27.1 Financial Data Schedule

     (b) The  Registrant  did not file any Current Report on Form 8-K during the
quarter ended September 30, 1998.

*Items omitted from this Form 10-Q/A  (Amendment No. 1) are either  included in
the Registrant's Quarterly  Report on Form 10-Q, as initially  filed, or are not
applicable.

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant has duly caused this amended report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  BIONX IMPLANTS, INC.


                                  By: /s/David W. Anderson
                                         David W. Anderson,
                                      President and Chief Executive Officer



                                  By: /s/ Michael J.  O'Brien
                                      Michael J. O'Brien
                                      Vice President, Chief Financial Officer
                                         and Chief Accounting Officer


Dated: November 19, 1998

<PAGE>


                                 EXHIBIT INDEX


Exhibit No.

Exhibit No. 27.1 Financial Data Schedule